<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title> &#187; Regulatory</title>
	<atom:link href="http://pharmaexecnews.com/category/pharmaceuticals/regulatory/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaexecnews.com</link>
	<description></description>
	<lastBuildDate>Fri, 29 Apr 2011 14:00:12 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Senators Resurrect Reimportation with New Bill</title>
		<link>http://pharmaexecnews.com/biotechnology/senators-resurrect-reimportation-bill/</link>
		<comments>http://pharmaexecnews.com/biotechnology/senators-resurrect-reimportation-bill/#comments</comments>
		<pubDate>Wed, 02 Mar 2011 14:00:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11240</guid>
		<description><![CDATA[Two U.S. senators have revived the reimportation debate with a new bill co-sponsored by a bipartisan group of their fellows. Sen. Debbie Stabenow (D-Michigan) is teaming up with Sen. Olympia Snowe (R-Maine) on the proposal, which would allow U.S. pharmacies and drug wholesalers to source products from other countries with &#8220;tough safety standards.&#8221;

Allowing importation from [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/senators-resurrect-reimportation-bill/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Doctor-Patient Relationship Compromised by Facebook</title>
		<link>http://pharmaexecnews.com/biotechnology/doctorpatient-relationship-compromised-facebook/</link>
		<comments>http://pharmaexecnews.com/biotechnology/doctorpatient-relationship-compromised-facebook/#comments</comments>
		<pubDate>Tue, 21 Dec 2010 08:00:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10991</guid>
		<description><![CDATA[Researchers surveyed the Facebook activities of 405 postgraduate trainee doctors at Rouen University Hospital in France and found that almost three out of four had a Facebook profile. One in four logged on to the site several times a day, and half logged on several times a week.

Almost half believed that the doctor-patient relationship would [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/doctorpatient-relationship-compromised-facebook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Loses Battle in War Against e-cigarettes</title>
		<link>http://pharmaexecnews.com/biotechnology/fda-loses-battle-war-ecigarettes/</link>
		<comments>http://pharmaexecnews.com/biotechnology/fda-loses-battle-war-ecigarettes/#comments</comments>
		<pubDate>Wed, 15 Dec 2010 08:00:54 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Devices and Technology]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[MedWatch Safety Alerts]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10974</guid>
		<description><![CDATA[Electronic cigarettes are nicotine-delivery devices that include a heating element that vaporizes chemicals in replaceable plastic cartridges. Researchers at the University of California, Riverside recently evaluated five e-cigarette brands and, finding design flaws, lack of adequate labeling, and several concerns about quality control and health issues, concluded that e-cigarettes are potentially harmful and urged regulators [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/fda-loses-battle-war-ecigarettes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Docs Must Police Each Other in Social Media</title>
		<link>http://pharmaexecnews.com/biotechnology/docs-police-social-media/</link>
		<comments>http://pharmaexecnews.com/biotechnology/docs-police-social-media/#comments</comments>
		<pubDate>Tue, 07 Dec 2010 08:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10949</guid>
		<description><![CDATA[The American Medical Association wants doctors to blow the whistle on their peers who behave badly online. The new policy is likely a response to concerns about patient confidentiality in social media exchanges, writes Colin Zick in the Foley Hoag law blog.  &#8221;When physicians see content posted by colleagues that appears unprofessional they have a [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/docs-police-social-media/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Top 10 Phase III Failures of 2010</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/top-10-phase-iii-failures-2010/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/top-10-phase-iii-failures-2010/#comments</comments>
		<pubDate>Mon, 06 Dec 2010 08:00:19 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Companies]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10944</guid>
		<description><![CDATA[By Phase III, researchers are supposed to have a pretty good handle on just how promising an experimental therapy can be. There&#8217;s proof-of-concept data in the can and some clear indications of just how big a market a new drug can go on to capture.

But even if the odds of success are somewhat better, the [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/top-10-phase-iii-failures-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech&#8217;s Biggest R&amp;D Spenders 2010</title>
		<link>http://pharmaexecnews.com/biotechnology/biotechs-biggest-spenders-2010/</link>
		<comments>http://pharmaexecnews.com/biotechnology/biotechs-biggest-spenders-2010/#comments</comments>
		<pubDate>Fri, 03 Dec 2010 08:00:55 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Procedures]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10940</guid>
		<description><![CDATA[Big Pharma is a global business, with a host of players scattered throughout Europe, the U.S. and Asia. But Big Biotech was born and bred in the U.S. And despite considerable international diversification, the industry still has made-in-the-USA stamped into its DNA.

We analyzed the EU&#8217;s  Industrial R&#38;D Investment Scorecard and came up with the top [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/biotechs-biggest-spenders-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA&#8217;s Top Q4 Blockbuster Drug Decisions</title>
		<link>http://pharmaexecnews.com/biotechnology/fdas-top-q4-blockbuster-drug-decisions/</link>
		<comments>http://pharmaexecnews.com/biotechnology/fdas-top-q4-blockbuster-drug-decisions/#comments</comments>
		<pubDate>Tue, 30 Nov 2010 08:00:37 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10927</guid>
		<description><![CDATA[The FDA has some of its biggest decisions of the year looming in the next few months. The first new lupus drug in half a century, a blood-thinner with mega-blockbuster potential, controversial weight drugs and more are all up for regulatory decisions that can move markets and either throw a bucket of cold water or [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/fdas-top-q4-blockbuster-drug-decisions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Migraine Use for Botox Could be Worth $1B</title>
		<link>http://pharmaexecnews.com/biotechnology/biomedical/migraine-botox-worth-1b/</link>
		<comments>http://pharmaexecnews.com/biotechnology/biomedical/migraine-botox-worth-1b/#comments</comments>
		<pubDate>Fri, 29 Oct 2010 08:00:41 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10838</guid>
		<description><![CDATA[Allergan has done it. The FDA finally approved its wrinkle-fighter Botox as a treatment for migraines. The new indication could add $1 billion to its current annual sales of $1.3 billion, analysts say. &#8220;This is the most meaningful market expansion that the product has had since it was approved for cosmetic use,&#8221; Piper Jaffray&#8217;s David [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/biomedical/migraine-botox-worth-1b/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Protests Indian Licensing Proposal</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/pharma-protests-indian-licensing-proposal/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/pharma-protests-indian-licensing-proposal/#comments</comments>
		<pubDate>Thu, 14 Oct 2010 08:00:35 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10791</guid>
		<description><![CDATA[The Indian pharmaceutical industry has been shaken up lately, worried that multinational drugmakers will come in and completely take over their drug market. The fears aren&#8217;t unfounded; Big Pharma, after all, has been targeting the subcontinent as a key location for expansion, as sales-growth slows in the U.S. and Europe.

The country wants foreign investment in [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/pharma-protests-indian-licensing-proposal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GSK, Theravance report promising PhII data for Advair successor</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/gsk-theravance-report-promising-phii-data-advair-successor/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/gsk-theravance-report-promising-phii-data-advair-successor/#comments</comments>
		<pubDate>Fri, 01 Oct 2010 08:00:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10754</guid>
		<description><![CDATA[GlaxoSmithKline and partner Theravance (THRX) say that their planned successor for the blockbuster Advair turned in a positive performance in a mid-stage study involving 60 people with COPD. Significantly, the new drug&#8211;dubbed Relovair&#8211;outperformed Advair on a key measure that gauges lung function. And that bodes well for the therapy, which is now in late-stage trials [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/gsk-theravance-report-promising-phii-data-advair-successor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

